T. Rowe Price Reports 2.8% Stake in Alkermes
ALKERMES PLC reported a Schedule 13G/A amendment showing T. Rowe Price Associates, Inc. beneficially owned 4,664,563 shares of Common Stock, representing 2.8% of the class as stated in the filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ALKERMES PLC reported a Schedule 13G/A amendment showing T. Rowe Price Associates, Inc. beneficially owned 4,664,563 shares of Common Stock, representing 2.8% of the class as stated in the filing. The filing lists sole voting power of 4,650,687 shares and sole dispositive power of 4,664,563. The report is signed by Ellen York, Vice President, dated 05/15/2026.
Insights
T. Rowe Price reports a passive stake of 2.8% in ALKERMES PLC.
The amendment to Schedule 13G/A states T. Rowe Price Associates, Inc. beneficially owns 4,664,563 shares representing 2.8% of common stock, with 4,650,687 shares showing sole voting power. The filing affirms the filer denies beneficial ownership in its boilerplate clause.
Ownership at this scale is typical for institutional holders filing under Schedule 13G/A. Subsequent filings may show changes in position; any change in reported percent or voting/dispositive power would be disclosed in future amendments.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficially owned regulatory
sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does T. Rowe Price report in ALKS?
When was the Schedule 13G/A amendment for ALKS signed?
Is T. Rowe Price an individual or institutional filer in the ALKS filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.